---
id: 148
title: Streptococcus pneumoniae Infections
category: organisms
subcategory: gram_positive_cocci
tags: [pneumococcus, pneumonia, meningitis, vaccine, penicillin-resistance]
difficulty: medium
---

## Question

What are the key clinical syndromes and resistance patterns for *S. pneumoniae*? Use the **"#1 CAP, Meningitis → Pen-Susceptible: PCN/Ceftriaxone, Pen-Resistant: Vanc + Ceftriaxone"** framework.

## Answer

### ***Streptococcus pneumoniae* (Pneumococcus) Overview:**

**Colonization:** Upper respiratory tract (nasopharynx) in 5-10% adults, 20-40% children

**Risk Factors for Invasive Disease:**
- **Age:** <2 years, >65 years
- **Asplenia** (functional or anatomic) - highest risk
- **Immunocompromised:** HIV, malignancy, transplant, chronic steroids
- **Chronic diseases:** COPD, diabetes, heart/liver/kidney disease, CSF leak
- **Smoking, alcohol use disorder**

### **Clinical Syndromes:**

**Community-Acquired Pneumonia (CAP):**
- **Most common bacterial cause** (~30-40% of bacterial CAP)
- **Presentation:** Fever, productive cough (rust-colored sputum), pleuritic chest pain
- **CXR:** Lobar consolidation (classic), parapneumonic effusion/empyema
- **Complications:** Bacteremia (25-30%), empyema, lung abscess

**Meningitis:**
- **Most common bacterial meningitis** in adults (50% of cases)
- **High mortality:** 15-20% despite treatment
- **CSF:** Neutrophilic pleocytosis, ↑protein, ↓glucose
- **Complications:** Hearing loss, neurologic sequelae

**Bacteremia/Sepsis:**
- **Can occur without focal source** (primary bacteremia)
- **Associated syndromes:** Pneumonia, meningitis, endocarditis

**Otitis Media:**
- **Most common bacterial cause** in children (30-40%)

**Sinusitis:**
- Common cause alongside *H. influenzae*, *M. catarrhalis*

**Endocarditis:**
- **Rare** (non-typhi *Salmonella* more common for native valve IE from bacteremia)
- **Associated with alcoholism**

### **Treatment:**

**Penicillin Susceptibility:**

| MIC | Classification | Notes |
|-----|----------------|-------|
| **≤0.06 mcg/mL** | Penicillin-susceptible | ~70% of isolates |
| **0.12-1 mcg/mL** | Penicillin-intermediate | ~15% |
| **≥2 mcg/mL** | Penicillin-resistant | ~15% |

**Pneumonia (Non-Meningeal):**

**Penicillin-Susceptible (MIC ≤2 mcg/mL):**
- **Penicillin G 2-4 million units IV q4h** OR **ampicillin 1-2g IV q4-6h**
- **Ceftriaxone 1g IV daily** (alternative)

**Penicillin-Resistant (MIC ≥4 mcg/mL):**
- **Ceftriaxone 2g IV daily** (preferred for non-meningeal infections)
- **Levofloxacin 750mg IV/PO daily** OR **moxifloxacin 400mg IV/PO daily**
- **High-dose penicillin still effective** for non-meningeal disease (achieves lung concentrations)

**Meningitis:**

**Empiric (Before Susceptibilities):**
- **Vancomycin 15-20 mg/kg IV q8-12h** + **ceftriaxone 2g IV q12h**
- **Add dexamethasone 10mg IV q6h × 4 days** (start with/before first antibiotic dose)

**Definitive (Susceptibility-Based):**

| Susceptibility | Treatment | Duration |
|----------------|-----------|----------|
| **Pen-susceptible (MIC <0.06)** | **Penicillin G 4 million units IV q4h** OR **ampicillin 2g IV q4h** | 10-14 days |
| **Pen-intermediate/resistant** | **Ceftriaxone 2g IV q12h** + **vancomycin 15-20 mg/kg q8-12h** | 10-14 days |
| **Ceftriaxone-resistant (MIC ≥2)** | **Continue vancomycin + ceftriaxone** | Consider rifampin 600mg IV/PO daily |

**Bacteremia Without Focus:**
- **Treat as pneumonia** (duration 5-7 days if uncomplicated)

## Key Points

### **Resistance Mechanisms:**
- **Penicillin resistance:** Altered penicillin-binding proteins (PBPs)
- **NOT β-lactamase** (unlike *S. aureus*, *H. influenzae*)
- **Ceftriaxone usually remains active** even if penicillin-resistant

### **Why Dexamethasone in Meningitis:**
- **Reduces mortality** and neurologic sequelae (especially hearing loss)
- **Dose:** 10mg IV q6h × 4 days
- **Give with/before first antibiotic** (maximally effective if started early)

### **Vaccines:**

**PCV15/PCV20 (Pneumococcal Conjugate Vaccine):**
- **All infants:** 4-dose series (2, 4, 6, 12-15 months)
- **Adults ≥65 years:** PCV20 (single dose) OR PCV15 followed by PPSV23 (1 year later)
- **High-risk adults <65:** Same as ≥65 years

**PPSV23 (Pneumococcal Polysaccharide Vaccine):**
- **High-risk patients:** 1-2 doses (depends on indication)
- **Does NOT boost** if given before PCV (give PCV first in adults)

### **Asplenia = Highest Risk:**
- **Overwhelming post-splenectomy infection (OPSI):** Rapid progression to shock/death
- **Preventive strategies:**
  - **Vaccinate:** PCV20 (or PCV15 + PPSV23), meningococcal, *H. influenzae* type b, annual influenza
  - **Antibiotic prophylaxis:** Penicillin VK 250-500mg PO BID (lifetime or ≥2 years post-splenectomy)
  - **Patient education:** Seek care immediately for fever

### **Clinical Pearls:**
- **Most common bacterial CAP and meningitis** in adults
- **Penicillin-susceptible:** Penicillin G or ceftriaxone
- **Meningitis:** Vancomycin + ceftriaxone + dexamethasone (empiric)
- **Resistance via altered PBPs** (NOT β-lactamase)
- **Asplenia = highest risk** → vaccinate + consider penicillin prophylaxis
- **PCV20 recommended** for adults ≥65 years

## Sources

- [IDSA: Community-Acquired Pneumonia Guidelines 2024]
- [IDSA: Bacterial Meningitis Guidelines 2024]
- [CDC: Pneumococcal Vaccination 2024]

## Media

N/A
